Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Operating Results by Reportable Segment (Detail)

v3.19.1
Segment Information - Operating Results by Reportable Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Net Revenue $ 6,477 $ 5,903  
Direct cost of goods (1,884) (1,472)  
Research and development (23,273) (24,958)  
General and administrative (13,478) (13,548)  
Segment gain (loss) from operations (32,608) (34,172)  
Segment assets 200,538   $ 140,993
Assets held for sale     13,089
Total consolidated 200,538   $ 140,993
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 6,125 5,509  
Direct cost of goods (1,884) (1,472)  
Sales and marketing costs (3,493) (2,764)  
Research and development 0 0  
General and administrative (387) (397)  
Segment gain (loss) from operations 361 876  
Segment assets 11,079 11,163  
Total consolidated 11,079 11,163  
Pharmaceutical and Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 352 394  
Direct cost of goods 0 0  
Sales and marketing costs 0 0  
Research and development (23,723) (25,055)  
General and administrative (9,598) (10,387)  
Segment gain (loss) from operations (32,969) (35,048)  
Segment assets 189,459 189,560  
Total consolidated 189,459 189,560  
Consolidated [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 6,477 5,903  
Direct cost of goods (1,884) (1,472)  
Sales and marketing costs (3,493) (2,764)  
Research and development (23,723) (25,055)  
General and administrative (9,985) (10,784)  
Segment gain (loss) from operations (32,608) (34,172)  
Segment assets 200,538 200,723  
Assets held for sale 64,352    
Total consolidated $ 200,538 $ 200,723